
From: Robert Krukowski [/O=REGENERON/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=ROBERT.KRUKOWSKI]
Sent: Monday, November 25, 2013 1:54:40 PM
To: William Daniels
Subject: FW: CDF information
Importance: High

Here is what we need to discuss and address today with CDF. Please stop by when you're in Rob

From: John Calabro
Sent: Monday, November 25, 2013 8:54 AM
To: Robert Davis; Cathy Casey; Robert Krukowski
Cc: Thibault Corbin de Mangoux
Subject: CDF information
Importance: High

Bob/Cathy/Rob:

Just to confirm our conversation Friday. Here are the follow up items:

- Contact CDF to get any additional information regarding the changes made at CDF and to inquire as to whether they are under any governmental investigation.
- Request written confirmation of the products included in the wet AMD indication (should be EYLEA, Lucentis, Macugen, Visudyne), as well as the products currently offered in the DME and RVO (CRVO and BRVO) indications.
- Verify with Bill Daniels that he has not had any conversations with CDF concerning product level data or qualification criteria for the program.
- Confirm with Bill Daniels that CDF has not notified him of any governmental or regulatory finding that indicated CDF is not in compliance with the terms of our agreement.

In addition to the above, can you please forward me a copy (electronic if possible) of the monthly report of aggregate data we receive from CDF as well as documentation showing how they make their requests for additional funding.

Thanks again for your help,

John

John P. Calabro, CPA, CIA
Executive Director, Internal Audit
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Rd.
Tarrytown, NY. 10591
914-847-7986